{
    "ticker": "ENSC",
    "name": "Ensysce Biosciences, Inc.",
    "description": "Ensysce Biosciences, Inc. is a biopharmaceutical company focused on developing innovative pain management solutions that aim to reduce the risks associated with opioid use. Founded in 2014, Ensysce leverages its proprietary technologies to create safer and more effective analgesic medications. The company is particularly known for its unique drug delivery platform, which includes the use of advanced formulations designed to deter misuse and abuse of pain medications. Ensysce's lead product candidate, PF614, is a novel formulation of an approved opioid that has been engineered to reduce the potential for misuse and overdose. This approach is part of a broader strategy to address the escalating opioid crisis and provide patients with effective pain relief without the associated risks. The company is committed to advancing its pipeline of drug candidates through clinical trials and regulatory approval, with a focus on ensuring patient safety and improving the quality of life for those suffering from chronic pain. Ensysce's mission is to transform the treatment landscape for pain management while minimizing the societal impact of opioid misuse.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2014",
    "website": "https://www.ensysce.com",
    "ceo": "Dr. Lynn Kirkpatrick",
    "social_media": {
        "twitter": "https://twitter.com/EnsysceBio",
        "linkedin": "https://www.linkedin.com/company/ensysce-biosciences/"
    },
    "investor_relations": "https://www.ensysce.com/investors",
    "key_executives": [
        {
            "name": "Dr. Lynn Kirkpatrick",
            "position": "CEO"
        },
        {
            "name": "Mark A. S. B. Haller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pain Management Products",
            "products": [
                "PF614"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ensysce Biosciences, Inc. | Innovative Pain Management Solutions",
        "meta_description": "Ensysce Biosciences, Inc. develops innovative pain management solutions aimed at reducing opioid misuse. Explore our advanced drug delivery technologies and ongoing clinical trials.",
        "keywords": [
            "Ensysce",
            "Pain Management",
            "Opioids",
            "Biopharmaceuticals",
            "PF614"
        ]
    },
    "faq": [
        {
            "question": "What is Ensysce Biosciences known for?",
            "answer": "Ensysce Biosciences is known for developing innovative pain management solutions with a focus on reducing the risks associated with opioid use."
        },
        {
            "question": "Who is the CEO of Ensysce Biosciences?",
            "answer": "Dr. Lynn Kirkpatrick is the CEO of Ensysce Biosciences, Inc."
        },
        {
            "question": "Where is Ensysce headquartered?",
            "answer": "Ensysce is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is the lead product candidate of Ensysce?",
            "answer": "The lead product candidate of Ensysce is PF614, a novel formulation of an approved opioid designed to deter misuse."
        },
        {
            "question": "When was Ensysce founded?",
            "answer": "Ensysce was founded in 2014."
        }
    ],
    "competitors": [
        "ACAD",
        "APRI",
        "IRWD",
        "PTGX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}